As integral member of Chugai Pharmaceutical’s (Chugai) R&D projects, CPUSA contributes to the planning of global development programs and leads the execution of U.S. clinical programs, while leveraging external resources effectively and efficiently thus ensuring the safety and quality of clinical studies.

CPUSA is the primary contact and liaison with the U.S. Food & Drug Administration (FDA) for Chugai, and manages Chugai’s corporate strategies for communication and correspondences with the FDA in order to establish a good relationship. As part of Chugai’s R&D network, CPUSA supports Chugai in establishing and managing relationships with academia and clinical sites (key opinion leaders and investigators).

As the U.S. front-line force of Chugai, CPUSA provides immediate and proactive measures for prevention and correction of risks and issues for U.S. clinical development.

To learn more about Chugai’s R&D Pipeline & Activities, please use the menu links.